| ACEON® | |
| PHYSIOTENS® | |
| TEVETEN® This information is not intended for US residents |
| CREON® | |
| DICETEL® | |
| DUSPATAL® | |
| DUPHALAC® This information is not intended for US residents | |
| ROWASA® This information is not intended for US residents |
| DUPHASTON® | |
| ESTRATEST® | |
| FEMOSTON® | |
| PRESOMEN® | |
| PROMETRIUM® |
| INFLUVAC® |
| LUVOX® This information is not intended for US residents | |
| SERC® |
| International Marketing | |
| Operations | |
| USA | |
| Europe | |
| Japan | |
| Manufacturing | |
| Research and Development |
| Growth of existing products | |
| Development of new products | |
| Acquisition of new products | |
| Geographical expansion | |
| US | |
| Japan | |
| Worldwide | |
| Strategic alliances in marketing and R&D |
| Corporate Offices | |
| Regional Offices | |
| Manufacturing Sites | |
| Research Sites | |
| Sales Organizations Worldwide |
| In Depression and Anxiety | |
| In Schizophrenia | |
| In Cardiovascular Disease | |
| In Irritable Bowel Syndrome | |
| In Delayed Gastric Emptying | |
| In Pancreatic Exocrine Insufficiency | |
| In Hormone Replacement |
| The Challenge | |
| Solvay Pharmaceuticals’ approach | |
| Targeted Approach |